Overview
CLDI market data
Price History
CLDI price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$65.49 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.38 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.10 – $10.92 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $2 · P/B 2.23.
Company news
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving PremarketBenzinga · Jul 21, 2026, 9:11 AM
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026Globenewswire Inc · Jul 20, 2026, 9:30 PM
Calidi Biotherapeutics shares are trading lower after the company announced a 1-for-16 reverse stock split.Benzinga · Jul 20, 2026, 8:32 PM
Calidi Effects 1-For-16 Reverse Stock Split In July 31, 2026Benzinga · Jul 20, 2026, 8:31 PM
Calidi Biotherapeutics Presents Data On Its Approach Of Simultaneously Activating T-cells While Inducing Expression Of T-Cell Engagers Specifically In Situ In Tumor MicroenvironmentBenzinga · Jun 24, 2026, 12:10 PM
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human StudyGlobenewswire Inc · Jun 16, 2026, 12:15 PM
Calidi Biotherapeutics Receives Pre-IND Regulatory Feedback From FDA Providing Alignment, Clarity On IND-Enabling Preclinical Plans And Clinical Strategy For CLD-401 Prior To Advancing Drug Candidate Into Phase 1 Clinical StudiesBenzinga · Jun 16, 2026, 12:10 PM
Calidi Biotherapeutics Provides Required NYSE American DisclosureGlobenewswire Inc · May 22, 2026, 10:15 PM
Calidi Biotherapeutics Q1 EPS $(0.43) Beats $(1.56) EstimateBenzinga · May 14, 2026, 8:58 PM